BioCam.ai

About: BioCam is disrupting the $38B gastrointestinal track screening market by cutting the examination time by 90% and enabling remote diagnosis.

As BioCam, we want to popularize capsule endoscopy as a patient-friendly remote examination of the digestive system supported by AI algorithms and implement a new standard of digestive system screening for humans and animals.

BioCam’s proprietary technology is enabling at-home, patient-friendly and affordable procedures for humans & animals, improving early detection of dangerous diseases, e.g. colorectal cancer. Their AI-based software not only dramatically improves efficiency (minutes not hours), but also gives the doctors a clear yes/no answer to whether an actual colonoscopy is required with an F-Score of 97%! Their technology will be ready for commercial deployment on the veterinary market in the middle of 2025. Currently, BioCam is preparing for veterinary commercialization pilots and is in process 3-year distribution agreements with partners among others in Poland, Lithuania, Latvia , Italy, UK, Sweden, France, Brazil, in Africa (Tunisia, Algeria, Morocco, Nigeria), UAE and Saudi Arabia
 

IP: AI algorithms & proprietary hardware solution will be patented

Team: 30+ professionals, including renown AI experts in medical imaging, high-class microelectronics & microoptics engineers as well as experienced business professionals